Namuscla
Mexiletine · Lupin Europe GmbH
ORPHAN AUTHORISED IN THE EUWhat Namuscla is used for
Namuscla is indicated for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Namuscla
- Active substance
- Mexiletine
- Disease area
- Myotonic Disorders
- Medicine group
- Cardiac therapy
- ATC code
- C01BB02
- Marketing authorisation holder
- Lupin Europe GmbH
- Authorised in the EU since
- 2018
Official information
In India
- Mexiletine hydrochloride: 6 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Namuscla used for?
Namuscla is indicated for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders.
What is the active substance in Namuscla?
Namuscla contains Mexiletine.
Who makes Namuscla?
The EU marketing authorisation holder is Lupin Europe GmbH.
Is Namuscla an orphan medicine?
Yes. Namuscla is designated an orphan medicine in the EU, for a rare disease (Myotonic Disorders).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU